- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03876314
Fysisk aktivitet, Alzheimers sjukdom och kognition i förhållande till APOE genotyp (PAAD-2)
Effekten av fysisk aktivitet på kognition i förhållande till APOE genotyp (PAAD-2)
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
North Carolina
-
Greensboro, North Carolina, Förenta staterna, 27402
- University of North Carolina-Greensboro
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Beskrivning
Inklusionskriterier:
- Familjehistoria om Alzheimers sjukdom, kognitiv funktionsnedsättning
- Kunna kommunicera på engelska
- Uppfyller för närvarande inte rekommendationerna för fysisk aktivitet (rekommendationerna är att träna 3 dagar/vecka i 30+ minuter per dag i mer än 3 månader)
- Villig att randomiseras till båda studievillkoren
- Villig att genomföra alla studieaktiviteter under 1 år
Exklusions kriterier:
- Uppfylla kriterierna för klinisk kognitiv funktionsnedsättning
- Kan inte utföra fysisk aktivitet på grund av känd kardiovaskulär, metabolisk eller njursjukdom och är symtomatiska eller på grund av ortopediska begränsningar
- Självrapportering av förvirrande neurologiska, psykiatriska eller aktiva allvarliga eller funktionshindrade neurologiska eller medicinska sjukdomar eller andra tillstånd som kan begränsa träning eller utgöra en fara för patienten
- Nuvarande användning av mediciner för att behandla symtom på Alzheimers sjukdom, som negativt påverkar kognitionen eller som påverkar hjärtfrekvensen
- Uppfyll kriterierna för depression med den korta formen av Center for Epidemiological Studies Depression Scale
- Reser under en längre period (>1 månad) under studietiden
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Physical Activity Condition (PAC)
Försökspersoner kommer att uppmanas att delta i virtuella träningspass 3 gånger i veckan under 1 år.
|
Ämnen kommer att delta i virtuella gruppövningar 3 gånger i veckan under 1 år.
Varje försöksperson kommer att uppmuntras att gå med måttlig intensitet (målpuls (HR) = 40-59 % HR-reserv) beroende på vilopuls och ålder.
Försökspersonerna kommer att utföra aerob träning på egen hand och motståndsövningar kommer att genomföras i virtuella träningspass med en instruktör 1 timme/dag i 3 dagar/vecka under 1 år.
Vid träningspassen kommer dessa deltagare att bli ombedda att registrera mått på genomförda övningar och kan bli ombedda att ge mått på hjärtfrekvens (bedömd genom palpation i 20 sekunder) och hastighet av upplevd ansträngning (RPE).
De kommer att uppmanas att skicka in träningsloggar med denna information.
Data från träningsloggar och träningsspecialister kommer att granskas för bevis på progression, konsekvent uppnående av måttlig intensitet och med avseende på den föreskrivna varaktigheten för aeroba- och styrketräningskomponenterna.
|
|
Inget ingripande: Usual Care Control (UCC)
Deltagare i den vanliga vårdkontrollen kommer att behålla sina normala hälsopraxis i 1 år.
Deltagarna kommer att få ett hälsonyhetsbrev varannan vecka och kommer att kontaktas varannan vecka för att svara på eventuella frågor och fråga om deltagarens hälsa.
Deltagarnas självrapporterade fysiska aktivitet kommer att bedömas varje månad.
På detta sätt kommer deltagarna att kontaktas av personal varje vecka.
Vanliga vårdkontrolldeltagare som genomför alla studierelaterade aktiviteter inklusive för-, mitt- och eftertest kommer att få ett kortvarigt YMCA-medlemskap efter eftertestet.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Performance on the Cognitive Domain of Executive Function as Measured With Stroop Interference Reaction Time (RT)
Tidsram: Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in executive function will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on Stroop Interference.
Stroop interference is calculated using reaction time (RT) data from correct trials and the following formula: Stroop Interference RT = Stroop Incongruent RT - (average (Stroop Congruent RT , Stroop Neutral RT)).
Stroop Congruent is also known as Stroop Word, and Stroop Neutral is also known as Stroop Color.
RT is recorded in msec and a larger score is indicative of greater interference (worse performance)
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Executive Function as Measured With Trail Making Test Interference
Tidsram: Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in executive function will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the Comprehensive Trail Making Test (TMT) interference.
TMT interference is calculated as total time to complete TMT B (also called Trail 5) minus the total time to complete TMT A (also called Trail 1)which were both recorded in seconds.
TMT interference is, therefore, recorded in seconds with a larger score indicative of greater interference (worse performance)
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Executive Function as Measured With NIH Toolbox Dimensional Change Card Sort
Tidsram: Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in executive function will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the NIH Toolbox Dimentional Change Card Sort Test (DCCS).
We used the recommended outcome of the DCCS computed score.
This is calculated automatically within the NIH Toolbox based upon a two-stage process combining a score of 0-5 from the accuracy data with a score of 0-5 from the reaction time data.
Thus, scores range from 0-10 with a higher score indicative of better performance.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Executive Function as Measured With the NIH Toolbox Flanker Test.
Tidsram: Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in executive function will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the NIH Toolbox Flanker Inhibitory Control and Attention Test.
We used the recommended outcome of the Flanker computed score.
This is calculated automatically within the NIH Toolbox based upon a two-stage process combining a score of 0-5 from the accuracy data with a score of 0-5 from the reaction time data.
Thus, scores range from 0-10 with a higher score indicative of better performance.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Memory as Measured With the Auditory Verbal Learning Test.
Tidsram: Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in memory will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the Auditory Verbal Learning Test.
Majdan et al. (1996) Form 1 was given at pre, the standard Rey Auditory Verbal Learning list was given at mid, and Majdan et al. (1996) Form 2 was given at post.
These versions are comparable in terms of their scores (Sherman, Tan, & Hrabok, 2022).
Possible scores range from 0-15 with a bigger score being indicative of better memory.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Memory as Measured With the Rey-Osterrieth Complex Figure Test
Tidsram: Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in memory will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the Rey Osterreith Complex Figure Test.
Tests were scored using the deep learning approach for automated scoring published by Langer et al. eLife 2024;13:RP96017.
DOI: https://doi.org/10.7554/eLife.96017.
Possible scores range from 0-36 with higher scores being indicative of better memory.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Memory as Measured With the NIH Toolbox Picture Sequence Test
Tidsram: Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in memory will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the NIH Toolbox Picture Sequence Memory Test - The computed score is an IRT-based theta score of the number of adjacent pairs placed for trial 1 and 2 with a higher score being indicative of better memory.
This score is automatically created within the NIH Toolbox.
Version A was given at pre, Version B was given at mid, and Version C was given at post.
Possible scores range from 200-700 with a higher score being indicative of better performance.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Memory as Measured With the Mnemonic Similarity Test
Tidsram: Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in memory will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) Lure Discimination Index (LDI) on the Mnemonic Similarity Test (MST).
The MST was created based upon the publicly available and validated instructions and stimuli provided by the creators of the task (Stark, Kirwan, & Stark, 2019).
Equivalent versions of the test are administered so participants see different stimuli at each testing session and those stimuli were counterbalanced to rotate through the different item types.
The formula for calculating the LDI is: p(similar|lure) - p(similar|foil) where p(similar|lure) = Total # of "similar" responses to lure items / 36 and p(similar|foil) = Total # "similar" responses to foil items / 36.
Scores range from -1 to +1 with a larger score indicating better discrimination performance.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Attention as Measured With the Paced Auditory Serial Addition Test
Tidsram: Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in attention will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the 2-sec trial of the Paced Auditory Serial Addition Task.
Scores are reported as the number of correct responses with possible scores ranging from 0-60 and larger scores being indicative of better attention.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Attention as Measured With the Forward Digit Span Test
Tidsram: Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in attention will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the Neurological Assessment Battery (NAB) Digit Span Forward test.
Scores are reported as the number of correct trials with possible scores ranging from 0-14 and larger scores being indicative of better attention.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Working Memory as Measured With NIH Toolbox List Sort Working Memory
Tidsram: Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in working memory will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the NIH Toolbox List Sort Working Memory Test.
Scores are reported as the sum of the total number of items correctly recalled and sequenced on Lists 1 and 2 with possible scores ranging from 0-26 and larger scores being indicative of better working memory.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Working Memory as Measured With Spatial Working Memory
Tidsram: Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in working memory will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) reaction time on the 4-dot trial of the Spatial Working Memory Test.
Scores are reported as the average reaction time (RT) for correct responses.
Smaller scores are indicative of faster performance (i.e., better performance).
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Working Memory as Measured With Backward Digit Span
Tidsram: Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in working memory will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) accuracy on the Neurological Assessment Battery (NAB) Digit Span Backwards test.
Scores are reported as the number of correct trial with possible scores ranging from 0-14 and larger scores being indicative of better working memory.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Processing Speed as Measured With the Digit Symbol Modalities Test (SDMT)
Tidsram: Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in working memory will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the Digit Symbol Modalities Test (SDMT) (Smith, 1973).
Scores are reported as the sum of Oral and Written Trial Raw Scores (correct responses) with possible scores ranging from 0-220 and larger scores being indicative of better working memory.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Processing Speed as Measured With the Stroop Word Test
Tidsram: Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in processing speed will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on Stroop Word condition (also known as the Stroop Congruent condition).
RT is recorded in msec and a larger score is indicative of slower performance (worse performance)
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Processing Speed as Measured With the Stroop Color Test
Tidsram: Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in processing speed will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on Stroop Color condition (also known as the Stroop Neutral condition).
RT is recorded in msec and a larger score is indicative of slower performance (worse performance)
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Processing Speed as Measured With the Trail Making Test A
Tidsram: Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in executive function will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on the Comprehensive Trail Making Test (TMT) A (TMT A) (also known as Trail 1).
Performance is recorded in seconds with a larger score indicative of slower performance (worse performance)
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Performance on the Cognitive Domain of Executive Function as Measured With Matrix Reasoning.
Tidsram: Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Change in executive function will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) performance on Matrix Reasoning Accuracy from the Virginia Cognitive Aging Project (VCAP).
Version O was given at pre, Version A was given at mid, and Version B was given at post.
Possible scores are proportions that range from 0-1 (i.e., 0% accuracy to 100% accuracy expressed on a 0.00-1.00
scale) with a higher score being indicative of better performance.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Brain Morphology (Whole Brain Volume)
Tidsram: Pre-Test and Post-Test (~12 months)
|
Change in whole brain morphology will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) for total segmented brain volume (i.e., total brain separated from non-brain structures).
This is measured as volume (mm3), with volumes ranging from 1,050,000 to 1,350,000, and with higher values being interpreted as better.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Brain Morphology (Left Hippocampus Volume)
Tidsram: Pre-Test and Post-Test (~12 months)
|
Change in Left Hippocampus Volume will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) for total segmented left hippocampus volume (i.e., left hippocampus segmented away from other regions).
This is measured as volume (mm3), ranges from 2500 to 4500, and higher values are better.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Brain Morphology (Right Hippocampus Volume)
Tidsram: Pre-Test and Post-Test (~12 months)
|
Change in Right Hippocampus Volume will be assessed by comparing Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months) for total segmented right hippocampus volume (i.e., right hippocampus segmented away from other regions).
This is measured as volume (mm3), ranges from 2500 to 4500, and higher values are better.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Blood Biomarkers (BDNF, Irisin, IGF-1, Glucose, Insulin, TNF-⍺, Serum Amyloid Protein (SAP), Albumin, ApoE and ⍺-2 Macroglobulin) - BDNF
Tidsram: Pre-Test and Post-Test (~12 months)
|
Blood samples will be taken following a 12-hour fast.
Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-⍺, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and ⍺-2 macroglobulin.
Change from pre-test to post-test will be assessed.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Blood Biomarkers (BDNF, Irisin, IGF-1, Glucose, Insulin, TNF-⍺, Serum Amyloid Protein (SAP), Albumin, ApoE and ⍺-2 Macroglobulin) - Irisin
Tidsram: Pre-Test and Post-Test (~12 months)
|
Blood samples will be taken following a 12-hour fast.
Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-⍺, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and ⍺-2 macroglobulin.
Change from pre-test to post-test will be assessed.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Blood Biomarkers (BDNF, Irisin, IGF-1, Glucose, Insulin, TNF-⍺, Serum Amyloid Protein (SAP), Albumin, ApoE and ⍺-2 Macroglobulin) - IGF-1
Tidsram: Pre-Test and Post-Test (~12 months)
|
Change in blood biomarkers (BDNF, irisin, IGF-1, glucose, insulin, TNF-⍺, serum amyloid protein (SAP), albumin, ApoE and ⍺-2 macroglobulin) - IGF-1. Blood samples will be taken following a 12-hour fast. Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-⍺, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and ⍺-2 macroglobulin. Change from pre-test to post-test will be assessed. The capture antibodies in the kits we received from the company for IGF-1 were not effective. We attempted to secure new kits to conduct the assays, but did not receive the kits in a timely fashion. We intend to conduct these assays upon receipt of the kits and the availability of personnel to perform the assays. The anticipated reporting date for IGF-1 is January 2027. |
Pre-Test and Post-Test (~12 months)
|
|
Change in Blood Biomarkers (BDNF, Irisin, IGF-1, Glucose, Insulin, TNF-⍺, Serum Amyloid Protein (SAP), Albumin, ApoE and ⍺-2 Macroglobulin) - Glucose
Tidsram: Pre-Test and Post-Test (~12 months)
|
Blood samples will be taken following a 12-hour fast.
Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-⍺, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and ⍺-2 macroglobulin.
Change from pre-test to post-test will be assessed.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Blood Biomarkers (BDNF, Irisin, IGF-1, Glucose, Insulin, TNF-⍺, Serum Amyloid Protein (SAP), Albumin, ApoE and ⍺-2 Macroglobulin) - Insulin
Tidsram: Pre-Test and Post-Test (~12 months)
|
Blood samples will be taken following a 12-hour fast.
Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-⍺, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and ⍺-2 macroglobulin.
Change from pre-test to post-test will be assessed.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Blood Biomarkers (BDNF, Irisin, IGF-1, Glucose, Insulin, TNF-⍺, Serum Amyloid Protein (SAP), Albumin, ApoE and ⍺-2 Macroglobulin) - TNFa
Tidsram: Pre-Test and Post-Test (~12 months)
|
Blood samples will be taken following a 12-hour fast.
Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-⍺, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and ⍺-2 macroglobulin.
Change from pre-test to post-test will be assessed.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Blood Biomarkers (BDNF, Irisin, IGF-1, Glucose, Insulin, TNF-⍺, Serum Amyloid Protein (SAP), Albumin, ApoE and ⍺-2 Macroglobulin) - SAA
Tidsram: Pre-Test and Post-Test (~12 months)
|
Blood samples will be taken following a 12-hour fast.
Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-⍺, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and ⍺-2 macroglobulin.
Change from pre-test to post-test will be assessed.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Blood Biomarkers (BDNF, Irisin, IGF-1, Glucose, Insulin, TNF-⍺, Serum Amyloid Protein (SAP), Albumin, ApoE and ⍺-2 Macroglobulin) - ALB
Tidsram: Pre-Test and Post-Test (~12 months)
|
Blood samples will be taken following a 12-hour fast.
Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-⍺, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and ⍺-2 macroglobulin.
Change from pre-test to post-test will be assessed.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Blood Biomarkers (BDNF, Irisin, IGF-1, Glucose, Insulin, TNF-⍺, Serum Amyloid Protein (SAP), Albumin, ApoE and ⍺-2 Macroglobulin) - ApoE
Tidsram: Pre-Test and Post-Test (~12 months)
|
Blood samples will be taken following a 12-hour fast.
Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-⍺, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and ⍺-2 macroglobulin.
Change from pre-test to post-test will be assessed.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Blood Biomarkers (BDNF, Irisin, IGF-1, Glucose, Insulin, TNF-⍺, Serum Amyloid Protein (SAP), Albumin, ApoE and ⍺-2 Macroglobulin) - ⍺-2 Macroglobulin
Tidsram: Pre-Test and Post-Test (~12 months)
|
Blood samples will be taken following a 12-hour fast.
Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-⍺, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and ⍺-2 macroglobulin.
Change from pre-test to post-test will be assessed.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Cardiorespiratory Fitness
Tidsram: Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
Fitness will be assessed by comparing predicted VO2max at Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months).
Fitness will be assessed using a submaximal graded aerobic exercise test performed on a treadmill.
Oxygen uptake (VO2) at each stage is estimated based on the treadmill speed and grade during a ramped exercise protocol performed until volitional exhaustion or test termination due to symptom limitations.
The VO2max estimation uses the slope of the regression line between the heart rates (HR) of the last two stages to extrapolate to the participant's predicted VO2 at their age-predicted max HR (220-age).
If HR at either of the last two stages is <110, VO2 could not be reliably calculated, and we consider the participant to have insufficient data (ID).
We have explored other options for estimating VO2 max, but believe this is the best option available.
|
Pre-Test, Mid-Test (~6 months), and Post-Test (~12 months)
|
|
Change in Brain Activity (Resting-state Connectivity) Right Lateral Parietal, Posterior Cingulate Cortex
Tidsram: Pre-Test and Post-Test (~12 months)
|
Functional MRI will be used to measure brain activity including resting-state connectivity and change will be assessed from pre-test to post-test.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Brain Activity (Resting-state Connectivity) Left Lateral Parietal, Right Lateral Parietal
Tidsram: Pre-Test and Post-Test (~12 months)
|
Functional MRI will be used to measure brain activity including resting-state connectivity and change will be assessed from pre-test to post-test.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Brain Activity (Resting-state Connectivity) Left Lateral Parietal, Posterior Cingulate Cortex
Tidsram: Pre-Test and Post-Test (~12 months)
|
Functional MRI will be used to measure brain activity including resting-state connectivity and change will be assessed from pre-test to post-test.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Brain Activity (Resting-state Connectivity) Medial Prefrontal Cortex, Posterior Cingulate Cortex
Tidsram: Pre-Test and Post-Test (~12 months)
|
Functional MRI will be used to measure brain activity including resting-state connectivity and change will be assessed from pre-test to post-test.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Brain Activity (Resting-state Connectivity) Medial Prefrontal Cortex, Right Lateral Parietal
Tidsram: Pre-Test and Post-Test (~12 months)
|
Functional MRI will be used to measure brain activity including resting-state connectivity and change will be assessed from pre-test to post-test.
|
Pre-Test and Post-Test (~12 months)
|
|
Change in Brain Activity (Resting-state Connectivity) Medial Prefrontal Cortex, Left Lateral Parietal
Tidsram: Pre-Test and Post-Test (~12 months)
|
Functional MRI will be used to measure brain activity including resting-state connectivity and change will be assessed from pre-test to post-test.
|
Pre-Test and Post-Test (~12 months)
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Jennifer Etnier, PhD, UNC Greensboro
Publikationer och användbara länkar
Allmänna publikationer
- Park KS, Etnier JL. An innovative protocol for the artificial speech-directed, contactless administration of laboratory-based comprehensive cognitive assessments: PAAD-2 trial management during the COVID-19 pandemic. Contemp Clin Trials. 2021 Aug;107:106500. doi: 10.1016/j.cct.2021.106500. Epub 2021 Jul 2.
- Park KS, Ganesh AB, Berry NT, Mobley YP, Karper WB, Labban JD, Wahlheim CN, Williams TM, Wideman L, Etnier JL. The effect of physical activity on cognition relative to APOE genotype (PAAD-2): study protocol for a phase II randomized control trial. BMC Neurol. 2020 Jun 6;20(1):231. doi: 10.1186/s12883-020-01732-1.
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 18-0228
- R01AG058919 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Datadokumentation och avidentifierade data kommer att deponeras för delning i enlighet med tillämpliga lagar och förordningar. Data kommer att vara tillgängliga i ett avidentifierat anonymt tillstånd och i en .csv formatera. Data kommer att delas genom att exportera data från RedCap till en .csv fil arkiverad under studiens huvudutredares institutionella profil med University of North Carolina Greensboro (UNCG) University Libraries institutionella repository North Carolina Digital Online Collection of Knowledge and Scholarship (NC DOCKS).
Data kommer också att delas genom Global Alzheimer's Association Interactive Network (GAAIN), ett federerat datasystem utformat för att främja datadelning och utveckling av samarbeten för forskare som är intresserade av Alzheimers relaterade data. Intresserade forskare kan utforska metadata från PAAD-2 och från andra studier. Genom att bli partner kommer en beskrivning av PAAD-2 och länk för att kontakta huvudutredaren att göras tillgängliga på www.gaain.org.
Tidsram för IPD-delning
Kriterier för IPD Sharing Access
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ICF
- ANALYTIC_CODE
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .